Estamos no ar no ! Saiba mais

electroCore

ECOR

Valor de mercado US$ 70,8 mi

7,85 USD

-0,50

5,99%

No fechamento Atualizado 16 de out. 16:00 EDT

1 dia

-5,99%

5 dias

-19,73%

1 mês

-26,29%

3 meses

35,81%

6 meses

17,51%

No acumulado do ano

72,53%

1 ano

56,37%

5 anos

-46,53%

10 anos

-97,36%

Sobre: electroCore Inc is a bioelectronic technology company whose mission is to improve health and quality of life through non-invasive bioelectronic technologies. Its two commercial products are gammaCore non-invasive vagus nerve stimulation, or nVNS, and Quell Fibromyalgia, or Quell. It also sells Truvaga and TAC-STIM products, which are handheld, personal-use consumer products developed to promote general wellness and human performance. It operates in one segment: Bioelectronic Innovations. Geographically, it operates in the United States, the United Kingdom, Japan, and Other.

Funcionários: 83

Saúde Dispositivos médicos

Notícias

Positivo

Neutro

Negativo

Sentimento 3 meses

Positivo 27,3%

Neutro 63,6%

Negativo 9,1%

electroCore Has A Line Of Sight At Cash Breakeven

electroCore is showing operational and financial improvement, driven by sales force expansion and strong Quell Fibromyalgia growth. ECOR targets >30% FY26 revenue growth, 85%+ gross margins, and positive adjusted EBITDA by Q3/27 without further dilution. Key catalysts include FDA submissions for CIPN, PTSD label expansion, and broadening TAC-STIM sales to first responders and intelligence agencies.

electroCore Has A Line Of Sight At Cash Breakeven

Zacks Investment Research

electroCore (ECOR) Stock Jumps 6.9%: Will It Continue to Soar?

electroCore (ECOR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

electroCore (ECOR) Stock Jumps 6.9%: Will It Continue to Soar?

electroCore to Participate at H.C. Wainwright Global Investment Conference

ROCKAWAY, N.J., Sept. 10, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that management will participate in the H.C.

electroCore to Participate at H.C. Wainwright Global Investment Conference

electroCore, Inc. Appoints Joshua Lev and Mike Fox as Co-Chief Executive Officers

ROCKAWAY, N.J., Sept. 09, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company and leader in non-invasive vagus nerve stimulation technologies, today announced that it has appointed Joshua Lev and Mike Fox as Co-Chief Executive Officers and members of the Board of Directors, effective September 8, 2026.

electroCore, Inc. Appoints Joshua Lev and Mike Fox as Co-Chief Executive Officers

electroCore's Truvaga® Named Best Luxury Biohacking & Longevity Brand in the USA by Luxury Lifestyle Awards

Recognition highlights Truvaga's combination of patented non-invasive vagus nerve stimulation technology, thoughtful design and personalized wellness experience Recognition highlights Truvaga's combination of patented non-invasive vagus nerve stimulation technology, thoughtful design and personalized wellness experience

electroCore, Inc. (ECOR) Q2 2026 Earnings Call Transcript

electroCore, Inc. (ECOR) Q2 2026 Earnings Call Transcript

electroCore, Inc. (ECOR) Q2 2026 Earnings Call Transcript

electroCore Q2 Earnings Call Highlights

electroCore NASDAQ: ECOR reported second-quarter 2026 revenue of $9.5 million, up approximately 28% from $7.4 million a year earlier, as growth in Veterans Affairs prescription sales and direct-to-consumer Truvaga sales lifted results. The company raised its full-year revenue outlook to growth of more than 30% over 2025 and said it is targeting positive adjusted EBITDA in the third quarter of 2027.

electroCore Q2 Earnings Call Highlights

Zacks Investment Research

electroCore, Inc. (ECOR) Reports Q2 Loss, Tops Revenue Estimates

electroCore, Inc. (ECOR) came out with a quarterly loss of $0.33 per share versus the Zacks Consensus Estimate of a loss of $0.41. This compares to a loss of $0.35 per share a year ago.

electroCore, Inc. (ECOR) Reports Q2 Loss, Tops Revenue Estimates

electroCore Announces Second Quarter 2026 Financial Results

Second quarter 2026 net sales of $9.5 million, an increase of 28% over $7.4 million in the second quarter 2025 Net loss of $3.1 million decreased 17% from prior year with Adjusted EBITDA net loss improving 26% from prior-year period Increasing 2026 revenue guidance to greater than 30% year-over-year growth Company to host a conference call and webcast today, August 6, 2026, at 4:30 pm EDT ROCKAWAY, N.J., Aug. 06, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR) (“electroCore” or the “Company”), a bioelectronic technology company, today announced financial results for the second quarter ended June 30, 2026.

electroCore Announces Second Quarter 2026 Financial Results

electroCore to Participate in Upcoming Investor Conferences

ROCKAWAY, N.J., Aug. 03, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that management will participate in the following investor conferences:

electroCore to Participate in Upcoming Investor Conferences

Ver ranking de notícias

Gráficos de preços implementados com Lightweight Charts™